Bayer’s Tightrope: A Supreme Court Ruling Hangs Over Promising Pharma Fundamentals

Bayer's pharma recovery and pipeline are overshadowed by glyphosate lawsuits. The upcoming Supreme Court ruling in Durnell could reshape 80% of cases. Stock down 27% from highs.

Bayer’s operational recovery is gaining traction, yet the stock continues to trade as if the company were fighting for survival. The disconnect stems from a single source: the glyphosate litigation that has cast a shadow over everything from product launches to cash flows. With the US Supreme Court expected to rule this month in the pivotal Durnell case, the tension between the group’s improving fundamentals and its legal albatross has rarely been starker.

On the operational front, the pharma division generated just over €4.2 billion in first-quarter revenue, matching the prior-year level, while the group’s adjusted top-line growth clocked in at 4%. Management is pinning its medium-term hopes on five potential blockbusters, including prostate cancer drug Nubeqa and kidney disease treatment Kerendia, which recently secured an accelerated FDA review for an expanded indication. The pipeline is beginning to offset declines from older products, and Bayer expects mid-single-digit pharma growth from 2027 onwards. Yet these achievements have been utterly ignored by equity markets, which have slashed the share price by more than 27% from its February high. The stock now changes hands at around €36.12, barely clinging to its 200-day moving average.

The market’s fixation is entirely legal. CEO Bill Anderson has escalated the confrontation by threatening to halt all US glyphosate production unless a durable legal solution is found — a move that would rattle American agriculture. The warning comes as plaintiffs’ attorneys push to move cases from Missouri to a federal court in California, where a judge perceived as hostile to Bayer presides. Management is fighting that relocation in court while lobbying for a political fix. Anderson remains committed to the integrated conglomerate structure, ruling out a spin-off of the Monsanto-derived Crop Science unit, even as pressure from major investors mounts. Union Investment recently voiced its exasperation, demanding “margins, not visions” — a clear signal that patience is wearing thin.

The forthcoming Supreme Court decision in the Durnell case is the single most important catalyst. JPMorgan analyst Richard Vosser estimates that a favourable ruling — which would centre on whether federal law pre-empts state-based failure-to-warn claims — could affect roughly 80% of the more than 100,000 outstanding glyphosate lawsuits. A win in Washington would fundamentally alter the legal landscape and open the door to a comprehensive settlement. But the risks are not confined to the US. In Brazil, lawyers are pushing for a complete ban on glyphosate, which, if successful, would dramatically expand the legal front. Meanwhile, the group’s free cash flow is being severely eroded by settlement payouts, diverting funds that could otherwise fuel R&D and growth.

Bayer’s market capitalisation stands at roughly €33.5 billion — a modest valuation for a group with this breadth of operations. But the asymmetry of the current bet is unmistakable: investors are not buying a pharma turnaround or a crop science revival; they are buying a legal outcome. If the Supreme Court rules in Bayer’s favour, the stock could re-rate sharply as the litigation overhang lifts. If it does not, Anderson’s threat to halt US glyphosate production could shift from rhetoric to reality, putting the company’s American agricultural business on a knife-edge. For now, the countdown in Washington continues to dictate the only number that matters.